Remove 2006 Remove Leads Remove Pharma
article thumbnail

Chiesi expands rare disease portfolio with Amryt Pharma acquisition

pharmaphorum

is to acquire the 2015-established Amryt Pharma Plc. Supported by voting agreements from leading Amryt shareholders and directors, and unanimously approved and recommended by the boards of both companies, the total transaction is worth up to $1.48 Biopharma and healthcare group Chiesi Farmaceutici S.p.A. on 6 th January.

Pharma 85
article thumbnail

Making an Impact During Disease Awareness Days, Weeks, and Months

PM360

Pharma marketers often turn to disease awareness days, weeks, and months to inform campaigns as they strategize for the year ahead. To the pharma marketing industry, these days and months present a clear opportunity to shed light on a particular condition or therapeutic area. Where Should Pharma Marketers Begin?

Media 92
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

How can the pharma industry address the gap in talent recruitment and development?

pharmaphorum

Furthermore, by simulating real-life scenarios, AR offers the chance for staff in the pharma industry to practice complex operations without the associated risks. For instance, in pharmaceutical manufacturing, mistakes in training can lead to contamination or waste, which can cause businesses unnecessary headaches.

article thumbnail

Market outlook to 2032: future trends across the seven major markets

European Pharmaceutical Review

billion by 2023, driven by the launch of Merck’s Belsomra and Eisai’s lemborexant (E-2006). GlobalData’s Analyst covering Neurology and Ophthalmology, Thomas Parker, MPharmacol, predicted that Belsomra would lead the market by 2023. million in sales by 2032. million in sales by 2032.

article thumbnail

Building agile partner relationships at a vaccine-focused biotech

pharmaphorum

They also discuss the changing world of commercial partnership in pharma, and how VBI and Syneos work together in an agile way. They reflect on the traditional “build or buy” dichotomy and how more complex relationships are possible – if not necessary – in today’s complicated pharma landscape. Baxter joined VBI in September of 2009.

article thumbnail

Drug pricing increases are disgraceful

World of DTC Marketing

Pharma companies continue to be among the most profitable industries, even outperforming tech companies. The Pharma Spin. Pharma continues to spin the lie about the high development costs of drugs but an analysis tells us the truth. This is an industry that doesn’t care about what people think of them.

Insurance 181
article thumbnail

After loss of exclusivity, small-molecule generics bite quick and hard, while biologics remain resilient

Clarivate

2: Patient flows for Humira versus generic competitors in France post-LOE Source: Clarivate Patient Data Intelligence “What we’re seeing here is the resilience of complex blockbuster biologics,” said Nicole Parisi, Clarivate Lead Business Analyst. In the U.S.,